КИМ Кюн Джин (US),ЖАО Вай-Менг (US),ПАРК Хангил (US),ВАСКЕЗ Маскимилиано (US)
申请号：
RU2011141890/10
公开号：
RU2011141890A
申请日:
2009.11.06
申请国别(地区):
RU
年份:
2013
代理人:
摘要：
1. A humanized monoclonal antibody or human monoclonal antibody (mAb) that binds to fibroblast growth factor receptor 2 (FGFR2) and inhibits the growth of human tumor xenograft in mice. The monoclonal antibody according to claim 1, which inhibits the binding of FGF2 to FGFR2.3. The monoclonal antibody according to claim 1, which binds to FGFR2IIIc, and not to FGFR2IIIc. The monoclonal antibody according to claim 1, which binds to both FGFR2IIIb and FGFR2IIIc. 5. The monoclonal antibody according to claim 1, which is a Fab or F (ab ') fragment or a single chain antibody. A pharmaceutical composition comprising a monoclonal antibody according to claim 1.7. A method for treating a malignant disease in a patient, comprising administering to said patient a pharmaceutical composition comprising the monoclonal antibody of claim 1.8. A monoclonal antibody (mAb) that competes for binding to FGFR2 with an antibody selected from the group consisting of GAL-FR21, GAL-FR22 and GAL-FR23, where the specified mAb is genetically engineered. 9. The monoclonal antibody of claim 8, which inhibits the growth of human tumor xenograft SNU-16 in mice. The monoclonal antibody of claim 8, which is chimeric or humanized. The monoclonal antibody of claim 8, which is a humanized GAL-FR21 or GAL-FR22 mAb. 12. The monoclonal antibody of claim 8, which is a human monoclonal antibody. A pharmaceutical composition comprising a mAb according to claim 8.14. A method for treating a malignant disease in a patient, comprising administering to said patient a pharmaceutical composition comprising a mAb according to claim 8.15. The method of claim 14, wherein said cancer is desire cancer1. Гуманизированное моноклональное антитело или моноклональное антитело человека (mAb), которое связывается с рецептором 2 фактора роста фибробластов (FGFR2) и ингибирует рост опухолевого ксенотрансплантата человека у мышей.2. Моноклональное антитело по п.1, которое ингибирует связывание FGF2 с FGFR2.3. Моноклональное антите
